Only HLA-A0201 positive patients whose tumor was positive for the expression of MART-1 at the protein level, and whose TIL contained at least 0.1% MART-1 reactive CD8+ T cells qualified to enroll on turnstile II, to proceed with large scale TIL expansion and infusion. Here, CD8A is linked to neoplasm.